Cargando…

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis

Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0

Detalles Bibliográficos
Autores principales: Karampitsakos, Theodoros, Papaioannou, Ourania, Dimeas, Ilias, Tsiri, Panagiota, Sotiropoulou, Vasilina, Tomos, Ioannis, Papanikolaou, Ilias C., Katsaras, Matthaios, Kirgou, Paraskevi, Daniil, Zoe, Gourgoulianis, Konstantinos I., Sampsonas, Fotios, Manali, Effrosyni, Papiris, Spyridon, Bouros, Demosthenes, Tzouvelekis, Argyris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990384/
https://www.ncbi.nlm.nih.gov/pubmed/35509438
http://dx.doi.org/10.1183/23120541.00082-2022
_version_ 1784683365308301312
author Karampitsakos, Theodoros
Papaioannou, Ourania
Dimeas, Ilias
Tsiri, Panagiota
Sotiropoulou, Vasilina
Tomos, Ioannis
Papanikolaou, Ilias C.
Katsaras, Matthaios
Kirgou, Paraskevi
Daniil, Zoe
Gourgoulianis, Konstantinos I.
Sampsonas, Fotios
Manali, Effrosyni
Papiris, Spyridon
Bouros, Demosthenes
Tzouvelekis, Argyris
author_facet Karampitsakos, Theodoros
Papaioannou, Ourania
Dimeas, Ilias
Tsiri, Panagiota
Sotiropoulou, Vasilina
Tomos, Ioannis
Papanikolaou, Ilias C.
Katsaras, Matthaios
Kirgou, Paraskevi
Daniil, Zoe
Gourgoulianis, Konstantinos I.
Sampsonas, Fotios
Manali, Effrosyni
Papiris, Spyridon
Bouros, Demosthenes
Tzouvelekis, Argyris
author_sort Karampitsakos, Theodoros
collection PubMed
description Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0
format Online
Article
Text
id pubmed-8990384
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-89903842022-04-11 Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis Karampitsakos, Theodoros Papaioannou, Ourania Dimeas, Ilias Tsiri, Panagiota Sotiropoulou, Vasilina Tomos, Ioannis Papanikolaou, Ilias C. Katsaras, Matthaios Kirgou, Paraskevi Daniil, Zoe Gourgoulianis, Konstantinos I. Sampsonas, Fotios Manali, Effrosyni Papiris, Spyridon Bouros, Demosthenes Tzouvelekis, Argyris ERJ Open Res Research Letters Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0 European Respiratory Society 2022-05-03 /pmc/articles/PMC8990384/ /pubmed/35509438 http://dx.doi.org/10.1183/23120541.00082-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Research Letters
Karampitsakos, Theodoros
Papaioannou, Ourania
Dimeas, Ilias
Tsiri, Panagiota
Sotiropoulou, Vasilina
Tomos, Ioannis
Papanikolaou, Ilias C.
Katsaras, Matthaios
Kirgou, Paraskevi
Daniil, Zoe
Gourgoulianis, Konstantinos I.
Sampsonas, Fotios
Manali, Effrosyni
Papiris, Spyridon
Bouros, Demosthenes
Tzouvelekis, Argyris
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
title Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
title_full Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
title_fullStr Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
title_full_unstemmed Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
title_short Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
title_sort reduced immunogenicity of the mrna vaccine bnt162b2 in patients with idiopathic pulmonary fibrosis
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990384/
https://www.ncbi.nlm.nih.gov/pubmed/35509438
http://dx.doi.org/10.1183/23120541.00082-2022
work_keys_str_mv AT karampitsakostheodoros reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT papaioannouourania reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT dimeasilias reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT tsiripanagiota reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT sotiropoulouvasilina reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT tomosioannis reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT papanikolaouiliasc reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT katsarasmatthaios reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT kirgouparaskevi reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT daniilzoe reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT gourgoulianiskonstantinosi reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT sampsonasfotios reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT manalieffrosyni reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT papirisspyridon reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT bourosdemosthenes reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis
AT tzouvelekisargyris reducedimmunogenicityofthemrnavaccinebnt162b2inpatientswithidiopathicpulmonaryfibrosis